Leo Wealth LLC Acquires 27,559 Shares of Pfizer Inc. $PFE

Leo Wealth LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 25.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,861 shares of the biopharmaceutical company’s stock after acquiring an additional 27,559 shares during the quarter. Leo Wealth LLC’s holdings in Pfizer were worth $3,383,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in PFE. MBA Advisors LLC grew its holdings in shares of Pfizer by 10.9% during the 4th quarter. MBA Advisors LLC now owns 21,798 shares of the biopharmaceutical company’s stock valued at $543,000 after purchasing an additional 2,151 shares during the last quarter. Walkner Condon Financial Advisors LLC raised its position in Pfizer by 5.1% in the 4th quarter. Walkner Condon Financial Advisors LLC now owns 9,485 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 457 shares during the period. Sowell Financial Services LLC lifted its stake in Pfizer by 3.2% in the fourth quarter. Sowell Financial Services LLC now owns 187,170 shares of the biopharmaceutical company’s stock worth $4,661,000 after purchasing an additional 5,747 shares during the last quarter. Stonebridge Financial Group LLC purchased a new stake in Pfizer during the fourth quarter valued at about $200,000. Finally, TOWER TRUST & INVESTMENT Co boosted its position in Pfizer by 4.5% during the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 21,403 shares of the biopharmaceutical company’s stock valued at $533,000 after buying an additional 929 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2%

Shares of Pfizer stock opened at $28.37 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.75. The company has a market cap of $161.29 billion, a P/E ratio of 20.86 and a beta of 0.43. The company’s fifty day simple moving average is $27.09 and its two-hundred day simple moving average is $25.84.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company posted $0.63 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Bank of America decreased their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, Morgan Stanley set a $27.00 price objective on Pfizer and gave the company a “positive” rating in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.